Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

Launched by CLINICAL HUB FOR INTERVENTIONAL RESEARCH (CHOIR) · Jan 14, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on finding new ways to treat patients with Acute Myeloid Leukemia (AML), a type of cancer that affects the blood and bone marrow. Researchers want to see if they can use special mice that accept human tissue to test different drug combinations that might work better for killing cancer cells. The study aims to answer important questions about how quickly new treatments can be discovered and whether the responses in these mice reflect how individual patients respond to treatment.

To participate in this study, you need to be at least 18 years old and have a confirmed diagnosis of AML. If you are currently receiving standard treatment with the medications venetoclax and azacitidine, you may be eligible to donate blood and bone marrow samples for the research. Before starting, you will need to provide your written consent to ensure you understand what the study involves. Please note that the trial is not yet recruiting participants, but it offers a unique opportunity to contribute to the development of better treatment options for AML.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 years and above
• • 2. Patients with suspicion of AML requiring screening procedures
• • 3. Documented diagnosis of AML by WHO Classification and/or International Consensus Classification.
• • Regardless of the number and type of prior lines of therapy or eligibility for allogeneic stem cell transplantation.
• • All AML subtypes are eligible.
• • Concurrent participation in clinical trials is allowed.
• • 4. Documented myeloblast percentage ≥20% in the bone marrow or peripheral blood within 12 weeks of C1D1 confirmed by bone marrow aspirate or peripheral blood smear.
• • 5. Planned to commence venetoclax and azacitidine therapy.
• • 6. Provision of written informed consent prior to any study-related assessments or procedures being carried out.
• Exclusion Criteria:
• • 1. Presence of any condition that, by assessment of the Investigator, would compromise the safety of the patient if they participated, the quality of trial data, or their adherence to the study-specified procedures.